For the quarter ending 2025-09-30, MIRM had $53,899K increase in cash & cash equivalents over the period. $39,494K in free cash flow.
| Cash Flow | 2025-09-30 | 2025-06-30 |
|---|---|---|
| Net loss | 2,905 | -20,538 |
| Stock-based compensation | 18,127 | 34,271 |
| Depreciation and amortization | 6,062 | 12,108 |
| Inventory reserves and firm commitment losses | -540 | -2,349 |
| Amortization of debt discount and offering costs | 443 | 860 |
| Unrealized foreign exchange gain | 643 | 1,270 |
| Non-cash lease expense | 447 | 826 |
| Other | 345 | 674 |
| Accounts receivable | 3,146 | 25,901 |
| Prepaid and other current assets | 4,632 | 7,114 |
| Inventory | 1,159 | 5,007 |
| Other assets | 2,684 | 1,342 |
| Accounts payable, accrued expenses and other liabilities | 24,346 | 22,314 |
| Operating lease liabilities | -580 | -803 |
| Net cash provided by operating activities | 39,681 | 10,079 |
| Purchase of investments | 20,860 | 65,063 |
| Proceeds from maturities of investments | 18,820 | 42,497 |
| Purchase of property and equipment | 187 | 167 |
| Payments made for additions to intangible assets | 0 | 0 |
| Net cash used in investing activities | -2,227 | -22,733 |
| Proceeds from issuance of common stock pursuant to equity plans | 16,096 | 15,047 |
| Net cash provided by financing activities | 16,096 | 15,047 |
| Effect of exchange rate on cash, cash equivalents and restricted cash | 349 | 3,281 |
| Net increase (decrease) in cash, cash equivalents and restricted cash | 53,899 | 5,674 |
| Cash and cash equivalents at beginning of period | 222,928 | - |
| Cash and cash equivalents at end of period | 282,501 | - |
Mirum Pharmaceuticals, Inc. (MIRM)
Mirum Pharmaceuticals, Inc. (MIRM)